Pembrolizumab, widely known by its brand name Keytruda, is one of the most important immunotherapy drugs used in modern cancer treatment. Unlike traditional chemotherapy, which directly targets cancer cells, Pembrolizumab works by empowering the immune system to recognize and attack tumors. It belongs to a class of treatments called immune checkpoint inhibitors, specifically targeting the PD-1 receptor on T cells.
Since its introduction, Pembrolizumab has transformed the treatment landscape for several cancers by offering longer-lasting and more durable responses in many patients.
In this article, we’ll explore what Pembrolizumab is, how it works, its major clinical uses, and the key safety considerations associated with this therapy.
I. What Is Pembrolizumab?
Pembrolizumab is a humanized monoclonal antibody used as an immunotherapy drug in the treatment of several types of cancer. It is designed to target PD-1 (Programmed Death-1), a receptor found on the surface of T cells, which are key players in the immune system. By blocking this receptor, Pembrolizumab helps restore the immune system’s ability to recognize and attack cancer cells.
Unlike chemotherapy, which directly kills rapidly dividing cells, Pembrolizumab works by modulating the immune response. This makes it part of a newer class of treatments known as immune checkpoint inhibitors, which have significantly changed how many cancers are managed.
Pembrolizumab gained attention because of its ability to produce durable responses in diseases where traditional treatments often fail. It has been approved for multiple cancer types, including melanoma, lung cancer, head and neck cancers, and bladder cancer. It is also used for tumors with specific biomarkers, such as high PD-L1 expression or MSI-high/dMMR status, making it an important drug in personalized cancer therapy.
II. How Pembrolizumab Works: Mechanism of Action
To understand how Pembrolizumab works, it’s important to look at how cancer cells evade the immune system. Normally, T cells patrol the body and destroy harmful or abnormal cells. However, many tumors develop strategies to “hide” from the immune system and avoid being attacked.
One of the most powerful escape mechanisms involves the PD-1/PD-L1 pathway.
- PD-1 is a receptor on the surface of T cells.
- PD-L1 is a protein that cancer cells often overexpress.
When PD-L1 on a tumor cell binds to PD-1 on a T cell, it sends a “brake” signal that tells the T cell to stop attacking. This allows cancer cells to survive and grow unchecked.
Pembrolizumab Blocks This Immune Brake
Pembrolizumab works by binding to the PD-1 receptor, preventing it from interacting with PD-L1. By blocking this connection, the drug removes the inhibitory signal that tumors use to shut down T cells. This process reactivates the immune system, allowing T cells to:
- Recognize cancer cells
- Proliferate
- Attack and destroy tumor tissue
This mechanism explains why Pembrolizumab can lead to long-lasting responses. Once T cells are reactivated, they can continue to patrol and eliminate cancer cells even after the tumor begins to shrink.
Why the Response Can Be Durable
Because Pembrolizumab enhances the immune system rather than directly killing cancer cells, it can create a memory effect within T cells. This helps prevent tumor regrowth in some patients, making it a powerful tool in long-term cancer control.
In summary, Pembrolizumab releases the brakes on the immune system, allowing it to do what it was designed to do: identify and destroy cancer cells.
III. Approved Clinical Uses of Pembrolizumab
Pembrolizumab has become one of the most widely used immunotherapy drugs because of its effectiveness across a broad range of cancers. Its approvals are based on its ability to improve survival, shrink tumors, and provide durable responses in many patients. Below are the major cancer types and clinical scenarios where Pembrolizumab is commonly used.
Melanoma
Pembrolizumab is one of the first-line treatments for advanced melanoma. It has significantly improved outcomes for patients with metastatic disease and is also used in the adjuvant setting to reduce the risk of recurrence.
Non–Small Cell Lung Cancer (NSCLC)
In lung cancer, Pembrolizumab is approved for:
- Advanced or metastatic disease
- Tumors with high PD-L1 expression
- Combination therapy with chemotherapy in broader groups
It has become a standard therapy in many first-line treatment regimens.
Bladder Cancer (Urothelial Carcinoma)
Pembrolizumab is used for:
- Advanced or metastatic bladder cancer
- Patients who cannot tolerate platinum-based chemotherapy
- Disease that progresses after initial chemotherapy
Head and Neck Squamous Cell Carcinoma
It is approved for both first-line and recurrent/metastatic settings, particularly in tumors with PD-L1 positivity.
Colorectal and Other Cancers With MSI-High/dMMR Biomarkers
Pembrolizumab is an important therapy for tumors that exhibit:
- Microsatellite instability–high (MSI-H)
- Deficient mismatch repair (dMMR)
These biomarkers indicate high mutational burden, making tumors more responsive to immune checkpoint blockade.
Other Approved Uses
Pembrolizumab also has indications in:
- Cervical cancer
- Gastric cancer
- Hepatocellular carcinoma
- Primary mediastinal large B-cell lymphoma
- Certain rare tumors like Merkel cell carcinoma
Monotherapy vs Combination Therapy
Depending on the cancer type, Pembrolizumab may be used:
- Alone, especially when PD-L1 expression is high
- In combination with chemotherapy, targeted therapy, or radiation
This flexibility contributes to its widespread adoption in oncology.
In summary, Pembrolizumab is approved across multiple cancer types and treatment settings, making it one of the best-established immunotherapies in modern oncology.
IV. Side Effects and Safety Considerations
Pembrolizumab is generally better tolerated than traditional chemotherapy, but because it works by activating the immune system, it can also cause the immune system to attack healthy tissues. These effects are known as immune-related adverse events (irAEs) and can involve almost any organ.
Common Side Effects
Some side effects are mild and occur in many patients, including:
- Fatigue
- Rash or skin itching
- Diarrhea
- Loss of appetite
- Joint or muscle pain
These are usually manageable and often improve with supportive care.
Immune-Related Side Effects
These occur when the immune system becomes overactive. They are less common but require careful monitoring:
1. Skin reactions
- Dermatitis
- Vitiligo (especially in melanoma patients)
2. Endocrine disorders
- Hypothyroidism or hyperthyroidism
- Adrenal insufficiency
- Diabetes caused by autoimmune attack on the pancreas
These conditions sometimes require long-term hormone replacement.
3. Gastrointestinal effects
- Immune-mediated colitis, which can cause persistent diarrhea or abdominal pain
4. Lung complications
- Pneumonitis, an inflammation of lung tissue that can be serious if untreated
5. Liver inflammation
- Hepatitis, detected through elevated liver enzymes
Why These Side Effects Occur
Because Pembrolizumab removes the PD-1 “brake,” T cells can become more active not only against cancer cells but also against healthy organs. This is a sign that the immune system is highly stimulated, but it must be controlled quickly to avoid complications.
Monitoring and Management
- Patients are monitored regularly through physical exams and blood tests.
- Most immune-related side effects can be managed with corticosteroids or temporary treatment interruption.
- Early detection is essential and helps prevent severe complications.
Despite these risks, many patients tolerate Pembrolizumab well, and the benefits often outweigh the potential side effects, especially in advanced cancers.
Conclusion
Pembrolizumab has become a cornerstone of modern cancer treatment thanks to its ability to reactivate the immune system and generate durable responses in many patients. By blocking the PD-1 pathway, it helps T cells recognize and eliminate cancer cells more effectively. While its immune-related side effects require careful monitoring, Pembrolizumab remains one of the most impactful therapies in oncology today. Understanding how this drug works and where it is used provides a solid foundation for exploring the growing field of cancer immunotherapy.
References
1. Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., … & Ribas, A. (2015). Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine, 372(26), 2521–2532. https://doi.org/10.1056/NEJMoa1503093
2. Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., … & Gandhi, L. (2015). Pembrolizumab for the treatment of non–small-cell lung cancer. New England Journal of Medicine, 372(21), 2018–2028. https://doi.org/10.1056/NEJMoa1501824
3. Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J. L., Fong, L., … & Powles, T. (2017). Pembrolizumab as second-line therapy for advanced urothelial carcinoma. New England Journal of Medicine, 376(11), 1015–1026. https://doi.org/10.1056/NEJMoa1613683
4. Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350–1355. https://doi.org/10.1126/science.aar4060
5. Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018). Next generation of immune checkpoint therapy in cancer: New developments and challenges. Journal of Hematology & Oncology, 11(1), 39. https://doi.org/10.1186/s13045-018-0582-8
6. National Cancer Institute. (n.d.). Pembrolizumab (Keytruda). National Institutes of Health. https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab
7. U.S. Food and Drug Administration. (n.d.). Keytruda (pembrolizumab) prescribing information. https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab
8. European Medicines Agency. (n.d.). Keytruda: Summary of product characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda
 is, how it works, its approved uses in cancer treatment, and the key side effects to know.){kind=link}